Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study
is to evaluate the following objectives in patients with advanced solid tumors after failure
of standard of care.